The study demonstrated that both rhThrombin and bThrombin had comparable efficacy, with 95 percent of patients in each treatment group achieving hemostasis within 10 minutes. The two treatments had similar safety profiles, although antibody development was significantly lower in patients treated with rhThrombin compared with bThrombin (1.5 percent versus 21.5 percent, respectively).
'/>"/>
| Contact: Sally Garneski pressinquiry@facs.org 312-202-5409 Weber Shandwick Worldwide Source:Eurekalert |